Genmab A/S is a Denmark-based pioneering international biotechnology company that develops differentiated antibody therapeutics. It aims to create innovative, targeted treatments for cancer and other severe diseases. The company conducts its research and development with a global operational reach.
Working in biotechnology and healthcare sectors, Genmab A/S leverages its proprietary antibody technologies, such as DuoBody and HexaBody platforms. Through this, it delivers novel therapeutic options aimed at improving patient outcomes and quality of life.
Keep an eye on the GMAB.CO share price by adding it to your eToro watchlist.
This content was generated by artificial intelligence. We cannot guarantee the accuracy, completeness, or timeliness of the information provided.